Latest News Feed

TIKOMED Granted Orphan Medicinal Drug Designation for ILB® for the Treatment of Amyotrophic Lateral Sclerosis by the European Commission
Press Release Aug 28, 2020
TIKOMED Granted Orphan Medicinal Drug Designation for ILB® for the Treatment of Amyotrophic Lateral Sclerosis by the European Commission
TIKOMED Secures 5M Euro Funding for the Clinical Development of ILB™ and IBSOLVMIR®
Press Release Mar 13, 2020
TIKOMED Secures 5M Euro Funding for the Clinical Development of ILB™ and IBSOLVMIR®
Locust Walk Appointed Strategic and Business Development Advisor for the Licensing Process of ILB™
Press Release Mar 9, 2020
Locust Walk Appointed Strategic and Business Development Advisor for the Licensing Process of ILB™
TFS International AB (TFS) Appointed CRO Representative for TIKOMED's Phase 2 Study in Clinical Islet Transplantation
Press Release Mar 4, 2019
TFS International AB (TFS) Appointed CRO Representative for TIKOMED's Phase 2 Study in Clinical Islet Transplantation
TIKOMED Successfully Closed Fundraising of 8 Million Euros
Press Release Feb 8, 2019
TIKOMED Successfully Closed Fundraising of 8 Million Euros
Shadow Lake Group Appointed Strategic Advisor and Business Development Representative for the Licensing Process of IBsolvMIR® in Canada
Press Release Feb 6, 2019
Shadow Lake Group Appointed Strategic Advisor and Business Development Representative for the Licensing Process of IBsolvMIR® in Canada
TIKOMED Granted Permission for Phase 2 Clinical Trial in Islet Cell Transplantation by the Swedish Medical Product Agency
Press Release Nov 19, 2018
TIKOMED Granted Permission for Phase 2 Clinical Trial in Islet Cell Transplantation by the Swedish Medical Product Agency
First Patient Treated With ILB in TIKOMED's Clinical Trial for ALS
Press Release Nov 2, 2018
First Patient Treated With ILB in TIKOMED's Clinical Trial for ALS
Tikomed to Initiate ALS Clinical Trial for Which the UK Medicines and Healthcare Products Regulatory Agency Has Granted Permission
Press Release Aug 20, 2018
Tikomed to Initiate ALS Clinical Trial for Which the UK Medicines and Healthcare Products Regulatory Agency Has Granted Permission
TIKOMED Announce Start of ALS Study at Sahlgrenska University Hospital
Press Release Aug 14, 2018
TIKOMED Announce Start of ALS Study at Sahlgrenska University Hospital
Press Release May 29, 2018
ILB - a Game Changer in Glaucoma
Press Release May 28, 2018
Tikomed Granted Permission for Clinical Trial in ALS by the Swedish Medical Product Agency and Ethical Review Board.
Press Release Dec 1, 2017
TikoMed Ready to Initiate Clinical Studies for Amyotrophic Lateral Sclerosis (ALS), Glaucoma, Alzheimer's, Traumatic Brain Injury (TBI), Stroke and Fibroproliferative Conditions (Scarring)
Press Release Dec 1, 2017
TikoMed Är Redo Att Sätta Igång Kliniska Studier Inom Amyotrofisk Lateralskleros (ALS), Alzheimers, Glaukom, Traumatisk Hjärnskada (TBI), Stroke Och Fibroproliferativa Tillstånd (Scarring)